Description: MeiraGTx is a clinical-stage genetic medicine company with a global footprint, is focused on developing potentially curative treatments for patients living with serious diseases.
Learn More
A recent piece by Mar de Miguel in BioWorld discusses the first “Spotlight on Immuno-Oncology” conference of the American Society of Gene & Cell Therapy (ASGCT) — with emphasis on MeiraGTx’s poster presentation marking the introduction of MeiraGTx’s CAR T technology, RiboCAR.
“MeiraGTx CAR T design is based on an orally available small molecule inducer that controls CAR expression to improve safety, efficacy, and durability,” writes de Miguel. “Their methodology resulted in naive T cells, which were less exhausted and more durable. . . . Unlike other modulable CARs that use chemicals for protein dimerization or viral protease, RiboCAR contains a synthetic Riboswitch ON created by Meiragtx, in which the aptamer acts as a sensor for a specific inducer. Without the inducer, CAR is
National Foundation of Swallowing Disorders | A community for those impacted by dysphagia
Leber Congenital Amaurosis Non-Profit | Hope in Focus
National Foundation of Swallowing Disorders | A community for those impacted by dysphagia
Sin City Swallow Conference 2015 – #ThickenedLiquidChallenge | National Foundation of Swallowing Disorders
Homepage - Global Genes